Nifty Smallcap 100 Plunges to 14,986 Low: Why Mid- and Small-Caps Are Crashing Harder Than the Market in March 2026

  The Indian stock market witnessed intense selling pressure on March 23, 2026, as mid- and small-cap indices tumbled over 4% amid a broader market crash driven by escalating geopolitical tensions in the Middle East. The Nifty Midcap 100 index has now declined around 13% year-to-date in 2026, reflecting sharp corrections in broader market segments that have outperformed in previous years but are now facing heightened volatility. Sharp Intraday Declines in Midcap and Smallcap Indices The Nifty Smallcap 100 index opened at 15,565.30 on Monday but quickly slipped to an intraday low of 14,986, erasing significant ground in early trade. By the afternoon session, the selling intensified, with the index down over 4% at points during the day. Market breadth was overwhelmingly negative—except for isolated performers like Trident (up around 2.85%), virtually every stock in the Nifty Smallcap 100 traded in the red, signaling widespread panic across smaller companies. Similarly, the Nifty M...
0

10 Promising Indian Companies in Pharma, Energy, and Finance Delivering Quarterly Surges to Watch Closely

 

The buzz in Dalal Street right now? It's all about companies that aren't just surviving 2025's volatility—they're thriving on it. With RBI's steady rates and export tailwinds, quarterly reports are unveiling hidden champions in pharma innovation, renewable energy, and niche finance. This roundup spotlights ten firms with double-digit growth stories, blending hard data with real-world catalysts. If you're scanning for stocks that could double your returns without the hype, read on. We've numbered them for easy tracking, complete with why they're on fire.

1. Torrent Pharmaceuticals: Pharma Powerhouse with US Ambitions

Torrent Pharma's Q1 FY26 profit leaped 20% to ₹54.8 crore on 11% revenue growth to ₹3,178 crore, led by diabetes and cardio drugs amid 8% domestic market expansion. Their US pipeline eyes 5-7 launches in FY26 for 10-15% topline boost, with EBITDA margins eyeing 32.5%. As chronic therapies dominate, Torrent's 56% India revenue share positions it for steady 12% CAGR— a prescription for reliable gains.

2. Tilaknagar Industries: Spirits Sector Sizzle with Premium Push

Toasting to success, Tilaknagar's Q2 FY25 revenue hit record highs with 26.5% volume growth, EBITDA up 39.1% to ₹66 crore (17.6% margin), and PAT surging 82% to ₹58 crore. Debt-free status and Andhra Pradesh market wins drove this, with premium brands like Mansion House gaining share. Post-Imperial Blue acquisition, expect 20%+ YoY growth—cheers to this liquor leader's buzz.

3. Thyrocare Technologies: Diagnostics Driving Health Boom

Thyrocare's Q1 FY26 sales rose 23.14% YoY to ₹197.68 crore, with PAT up 22.05% to ₹21.70 crore and 13.55% quarterly profit jump. Their franchise network hit 8,400, processing 6.7 million samples amid preventive health trends. Highest-ever operating profit of ₹57.70 crore in recent quarters signals 20% revenue growth potential—testing positive for investors.

4. Websol Energy: Solar Surge Amid Green Energy Rush

Websol's Q1 FY26 net sales hit ₹218.75 crore (record high), with PAT at ₹67.18 crore and PBT up 845% to ₹88.78 crore. Operating profit soared to ₹103.48 crore, backed by 595.58% YoY sales growth in prior quarters from polysilicon expansions. As India's solar targets climb, Websol's 445 MW capacity could beam 25%+ annual returns.

5. Banco Products: Cooling Solutions Heating Up Auto Exports

Banco's Q4 FY25 PAT exploded 125.21% to ₹153.50 crore on 22.34% sales growth to ₹893.44 crore, with 396.28% quarterly profit leap. ROE hit 30.08%, driven by radiator exports and EV tie-ups. Their 145% yearly stock run underscores margin magic—keep this auto ancillary on your radar for 20% FY26 upside.

6. KPI Green Energy: Renewables Ramping with Mega Sanctions

KPI Green's Q4 FY25 sales jumped 190.63% to ₹488.10 crore, with ₹3,200 crore SBI sanction for 1+ GWP solar projects. AUM-like inflows hit ₹3,500 crore (78% YoY), though pledges at 45.5% add caution. Hybrid IPP focus promises 30% growth—green energy's not just hot; it's electrifying portfolios.

7. India Shelter Finance: Affordable Housing's Steady Climb

India Shelter's Q3 FY25 AUM grew 36% YoY to ₹7,619 crore, disbursements up 29% to ₹879 crore at 6.1% margins. RoA and RoE at 5.6% and 14.3% reflect disciplined lending in Tier-2/3 markets. With 37% quarterly AUM rise, this NBFC is sheltering 20%+ profit growth amid housing booms.

8. Industrial Products: Steady Gains in Core Manufacturing

(Note: Interpreting as broader industrial plays; e.g., via proxies like those in manufacturing indices.) Industrial sectors clocked 3.3% Q2 GDP growth, with production up 0.1% in August amid 89% capacity utilization. Key players saw 20% construction spend rise to $238B, signaling quarterly absorption of 156.4M sq ft in 2025. Bet on this backbone for resilient 4-5% CAGR.

9. Insecticides India: Crop Protection's Resilient Harvest

Insecticides India's Q3 FY25 PAT rose 42% on 20% gross profit growth to ₹129.2 crore, revenue at ₹357.7 crore. Q1 FY26 sales up 5.41% to ₹695.04 crore, PAT 17.7% to ₹58.11 crore with 318.36% quarterly surge. Patented launches like Centran boost 3.54% market CAGR—pest control turning into profit shields.

10. Intellect Design Arena: Fintech Innovation Igniting Deals

Intellect's Q4 FY25 revenue grew 19% to ₹725.91 crore (consolidated), EBITDA at 30%, and 43 new wins with 53 go-lives. eMACH.ai platform drove 11% annual growth, cash at ₹1,000 crore. Special dividend of ₹3/share underscores strength—AI-fueled fintech for 15%+ FY26 trajectory.

From pharma pipelines to solar panels, these ten are scripting 2025's success stories with tangible quarterly firepower. Their blend of domestic dominance and global edges makes them must-watches.

Comments

Post a Comment